Quantcast
Last updated on April 23, 2014 at 12:16 EDT

Latest KRAS Stories

2013-02-12 04:20:51

SAN DIEGO, Feb. 12, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) today announced that the development of its proprietary, urine-based HPV carrier screening test is progressing well and the Company expects to achieve analytical and clinical validation of the test in its CLIA laboratory in March 2013. When validation is completed, the test will be available to clinicians and their patients. In addition to the ongoing HPV validation studies, one clinical trial has been completed...

2013-01-30 00:21:40

HILDEN, Germany and GERMANTOWN, Maryland, January 30, 2013 /PRNewswire/ -- - Momentum builds for therascreen(R)KRAS RGQ PCR Kit and Rotor-Gene Q MDx instrument - Clarient offers network of 2,000-plus pathologists testing with therascreen KRAS RGQ PCR Kit, the only FDA-approved KRAS companion diagnostic for Erbitux(R)in metastatic colorectal cancer - KRAS launch prepares way for QIAGEN's growing pipeline of Personalized...

2013-01-07 16:25:37

HILDEN, Germany and GERMANTOWN, Maryland, January 7, 2013 /PRNewswire/ -- - QIAGEN invests in new companion diagnostic being developed by Drug Response Dx that aims to predict efficacy of TNF-alpha inhibitors in rheumatoid arthritis patients - Rights to RET, ROS1 and DEPDC1 biomarkers gained from Insight Genetics offer promise as companion diagnostics in lung cancer - New tests from Inserm for mutations of HSP110 gene...

2012-11-30 16:11:11

A diagnosis of pancreatic cancer is particularly devastating since the prognosis for recovery is usually poor, with the cancer most often not detected until late stages. Research led by scientists at the University of California, San Diego and UC San Francisco Schools of Medicine examined the tumor-initiating events leading to pancreatic cancer (also called pancreatic ductal adenocarcinoma or PDA) in mice. Their work, published on line November 29 in the journal Cancer Cell, may help in...

2012-11-29 14:19:28

Researchers report that screening for KRAS and BRAF mutations can reduce the cost of anti-EGFR treatment for metastatic colorectal cancer but with a very small reduction in overall survival according to a new study published on November 28 in the Journal of the National Cancer Institute. Metastatic colorectal cancer patients whose tumors harbor mutations in KRAS (and to a lesser extent, in BRAF) are unlikely to respond to costly anti-EGFR therapies. Screening of patients who are...

2012-11-28 04:21:25

SAN DIEGO, Nov. 28, 2012 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) today announced successful development of its first molecular diagnostic test capable of detecting KRAS mutations from a urine specimen. Transfer of the transrenal KRAS test to the company's CLIA lab is expected to be completed in December 2012 with commercial availability expected in January 2013. (Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO) "Our scientific team has developed the first commercially...

2012-11-09 08:27:17

CALGARY, Nov. 9, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced three poster presentations covering expanded results from: a Phase II clinical trial using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours (REO 016), a Phase II clinical trial using intravenous administration of REOLYSIN( )in combination with...

2012-07-19 02:37:48

The Cancer Genome Atlas generates genomic data for colon and rectal cancers that point to potential targets for treatment The pattern of genomic alterations in colon and rectal tissues is the same regardless of anatomic location or origin within the colon or the rectum, leading researchers to conclude that these two cancer types can be grouped as one, according to The Cancer Genome Atlas (TCGA) project's large-scale study of colon and rectal cancer tissue specimens. In multiple types of...

2012-07-06 10:21:58

HILDEN, Germany, and GERMANTOWN, Maryland, July 6, 2012 /PRNewswire/ -- - U.S. launch of therascreen(R)KRAS RGQ PCR Kit offers enhanced approach to guide treatments for approximately 110,000 patients annually in U.S. with colorectal cancer - First FDA approval of a QIAGEN companion diagnostic marks a milestone in its global expansion of rapidly growing Personalized Healthcare business - Important cancer assay adds...

2012-07-03 02:22:53

SAN DIEGO, July 3, 2012 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a developer of trans-renal molecular diagnostics, announced today that they will be collaborating with The University of Texas MD Anderson Cancer Center on the detection of transrenal KRAS mutations in the urine of patients with pancreatic cancer. (Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO) According to recent estimates KRAS mutations are present in more than 90% of pancreatic cancers (1-3), and in...